alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 101–125 of 642 studies published 2011 (page 5 of 26) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Neuron 2011-09-21

The chromosome 9p21 amyotrophic lateral sclerosis-frontotemporal dementia (ALS-FTD) locus contains one of the last major unidentified autosomal-dominant genes underlying these common neurodegenerative diseases. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 63 out of 100. PloS one 2011-02-24

Recent GWAS studies focused on uncovering novel genetic loci related to AD have revealed associations with variants near CLU, CR1, PICALM and BIN1. 4 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Journal of Alzheimer's disease : JAD 2011-01-01

Poor vitamin D nutrition is linked with dementia, but vitamin D has not been tested in a randomized controlled trial (RCT) in Alzheimer's disease (AD). 4 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2011-03-01

Analysis of cross-sectional data from the AIBL study indicates that plasma apoE levels are altered in AD and correlate with AD pathology level. 5 key findings →

Design: cross-sectional Participants: 1,079 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2011-04-27

Changes in functional connectivity in DLB indicate patterns of activation that are distinct from those seen in AD and may improve discrimination of DLB from AD and cognitively normal individuals. 3 key findings →

Design: longitudinal study Participants: 88 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neuron 2011-09-21

Several families have been reported with autosomal-dominant frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), genetically linked to chromosome 9p21. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Risk of Continued Institutionalization After Hospitalization in Older Adults

✓ Peer-reviewed alzhub usefulness score 62 out of 100. The Journals of Gerontology Series A 2011-10-03

From 1996 through 2008, 5.55% of hospitalized patients resided in a nursing home 6 months later compared with 0.54% of nonhospitalized control patients. 5 key findings →

Design: retrospective cohort Participants: 762,243 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of hospice agency profit status with patient diagnosis, location of care, and length of stay

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA 2011-02-01

Compared with nonprofit hospice agencies, for-profit hospice agencies had a higher percentage of patients with diagnoses associated with lower-skilled needs and longer lengths of stay. 5 key findings →

Design: cross-sectional Participants: 4,705 Evidence: low

Full summary, score breakdown and related studies → Original source

Longitudinal neuroimaging correlates of subjective memory impairment: 4-year prospective community study

✓ Peer-reviewed alzhub usefulness score 62 out of 100. The British journal of psychiatry : the journal of mental science 2011-03-01

Complaints of poor memory by older people, particularly when new, may be a realistic subjective appraisal of recent brain changes independent of observed cognitive decline. 2 key findings →

Design: cohort study Participants: 1,336 Evidence: moderate

Full summary, score breakdown and related studies → Original source

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2011-04-21

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

✓ Peer-reviewed alzhub usefulness score 61 out of 100. The Lancet. Neurology 2011-03-01

In our training set, people with Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies had lower CSF α-synuclein concentrations than patients with Alzheimer's disease and other neurological disorders. 1 key finding →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months

✓ Peer-reviewed alzhub usefulness score 61 out of 100. International journal of geriatric psychiatry 2011-01-01

A framework for multi-centre MRI studies of Alzheimer's disease has been established consisting of a harmonized MRI acquisition protocol across centres, rigorous QC at both the sites and central data analysis hub and an automated image analysis pipeline. 4 key findings →

Design: longitudinal study Participants: 378 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A community-based exercise programme to improve functional ability in people with Alzheimer's disease: a randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Scandinavian journal of caring sciences 2011-05-12

Sixteen men and 24 women diagnosed with Alzheimer's disease participated in the study. 3 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Telephone-based identification of mild cognitive impairment and dementia in a multicultural cohort

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Archives of neurology 2011-05-01

The TICS has high diagnostic validity for identification of dementia among ethnically diverse older adults, especially when supported by the DQ and prior visit data. 2 key findings →

Design: longitudinal study Participants: 256 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Characterizing the RNA targets and position-dependent splicing regulation by TDP-43

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Nature neuroscience 2011-02-27

TDP-43 is a predominantly nuclear RNA-binding protein that forms inclusion bodies in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study

✓ Peer-reviewed alzhub usefulness score 61 out of 100. The Lancet. Neurology 2011-12-07

A locus on chromosome 9p21 has been associated with both disorders, and we aimed to identify the causal gene within this region. 3 key findings →

Participants: 305 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Four sensitive screening tools to detect cognitive dysfunction in geriatric emergency department patients: brief Alzheimer's Screen, Short Blessed Test, Ottawa 3DY, and the caregiver-completed AD8

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2011-04-01

Cognitive dysfunction, including dementia and delirium, is prevalent in geriatric emergency department (ED) patients, but often remains undetected. 4 key findings →

Design: cohort study Participants: 163 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Alzheimer s & Dementia 2011-04-22

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed